NASDAQ:AKBA

Akebia Therapeutics Stock News

etoro logo Buy AKBA
*Your capital is at risk
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first regulatory approval of vada
Local Chagrin Falls Businesses Facilitate Education by Launching a Healthy Home Webinar Series CHAGRIN FALLS, Ohio (PRWEB) June 24, 2020 Anne Capozzi, president of Capozzi Design Group of Chagrin
Akebia Therapeutics (NASDAQ:AKBA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday, Zacks.com reports. The firm presentl
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev
ROCKVILLE, MD / ACCESSWIRE / June 22, 2020 / The American Kidney Fund (AKF) today announced a new corporate membership program open to institutional partners that support AKF's core mission of fi
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the launch of AkebiaShares, a peer-to
Almost all the major components for manufacturing a smartphone are sourced from China, and are only assembled in India. That is the biggest challenge in becoming self-reliant on smartphone manufacturi
M&T Bank Corp increased its holdings in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 48.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exch
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on
When it comes to smartphones, India is only an assembly hub right now, and we remain dependent on nations such as China for critical components.
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced David A. Spellman is joining Akebi
Is (AKBA) Outperforming Other Medical Stocks This Year?

Expect fewer car launches in 2H20

01:30am, Tuesday, 16'th Jun 2020
Introducing new model is not a priority due to the high costs involved, says expert
by RAHIMI YUNUS/ pic by MUHD AMIN NAHARUL CARMAKERS must put their new launches on the back burner amid uncertai
Through combined expertise, organizations will further improve the quality of life for patients living with chronic kidney disease in Arizona
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE